Search
Novo Nordisk A/S
NVOAdd to Watchlist
48.190USD
0.0000.00%
Close 07-23 16:00（ET）Quotes delayed by 15 min
162.08BMarket Cap
11.27P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Novo Nordisk A/S is 6.86, ranking 122 out of 155 in the Pharmaceuticals industry. The average price target is 53.39, with a high of 90.39 and a low of 41.90.
Analyst Rating
Based on
14
analysts
Hold
Current Rating
50.013
Target Price
+1.28%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Novo Nordisk A/S
NVO
14
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Novo Nordisk A/S's expected revenue for the next quarter?
Novo Nordisk A/S's expected revenue is 10.97B.
What is Novo Nordisk A/S's price target?
Analysts forecast that Novo Nordisk A/S's price target is USD 53.39, with the highest forecast at USD 90.39 and the lowest forecast at USD 41.90.
How have Novo Nordisk A/SNVO's recent earnings per share performed?
The market expectation was USD 1.71, while Novo Nordisk A/SNVO's earnings per share (EPS) for the previous quarter was USD 0.94. EPS for the next quarter is expected at USD 0.76.
What is the analyst rating for Novo Nordisk A/S?
Based on the ratings of Novo Nordisk A/S's stock from 14 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.